iBio financials
$1.170.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '26 Jun 30 | Q3 '26 Mar 31 | Q2 '26 Dec 31 | Q1 '26 Sep 30 | Q4 '25 Jun 30 | Q3 '25 Mar 31 | Q2 '25 Dec 31 | Q1 '25 Sep 30 | Q4 '24 Jun 30 | Q3 '24 Mar 31 | Q2 '24 Dec 31 | Q1 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $100.0K | $200.0K | $0.00 | $200.0K | $0.00 | $175.0K | $0.00 | $0.00 | $50.0K |
| Gross profit | $0.00 | $0.00 | $0.00 | $100.0K | $200.0K | $0.00 | $200.0K | $0.00 | $175.0K | $0.00 | $0.00 | $50.0K |
| Gross margin | — | — | — | 100.0% | 100.0% | — | 100.0% | — | 100.0% | — | — | 100.0% |
| Operating income | -$11.4M | -$8.4M | $0.00 | -$6.0M | -$5.2M | -$4.9M | -$4.4M | -$4.1M | -$3.4M | -$3.6M | -$4.5M | -$5.1M |
| Net income | -$10.6M | -$7.8M | $0.00 | -$5.7M | -$5.2M | -$4.9M | -$4.4M | -$4.0M | -$7.8M | -$3.2M | -$8.2M | -$5.7M |
| Net margin | — | — | — | −5720.0% | −2581.5% | — | −2182.0% | — | −4444.6% | — | — | −11492.0% |
| Diluted EPS | $-0.04 | $-0.06 | $0.00 | $-0.11 | $-0.36 | $-0.49 | $-0.48 | $-0.46 | $-0.91 | $-0.85 | $-4.42 | $-4.80 |
| EBITDA | -$6.2M | -$8.2M | $0.00 | -$5.8M | -$5.1M | -$4.8M | -$4.3M | -$4.0M | -$3.5M | -$3.4M | -$4.2M | -$4.8M |
| Operating cash flow | -$6.2M | -$6.1M | -$5.2M | -$5.7M | -$4.6M | -$3.1M | -$3.9M | -$3.7M | -$4.9M | -$3.7M | -$4.7M | -$5.3M |
| Free cash flow | -$6.2M | -$6.1M | -$5.8M | -$5.7M | -$4.6M | -$3.1M | -$3.9M | -$3.7M | -$5.1M | -$3.7M | -$4.7M | -$5.3M |
| Diluted shares | 243.7M | 119.6M | — | 53.0M | 14.4M | 9.9M | 9.1M | 8.6M | 8.6M | 3.7M | 1.9M | 1.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $56.4M | $47.6M | $28.7M | $28.1M | $8.6M | $5.0M |
| Short-term investments | $31.6M | $27.2M | $24.0M | $21.5M | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $722.0K | $883.0K | $1.5M |
| Total assets | $99.1M | $85.8M | $64.4M | $64.2M | $23.2M | $19.1M |
| Total liabilities | $13.4M | $8.3M | $7.8M | $8.1M | $8.3M | $7.7M |
| Shareholders' equity | $85.7M | $77.5M | $56.6M | $56.0M | $14.9M | $11.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology